Improving cancer outcomes with Radioligand Therapies

POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.

Learn about POINT Biopharma

The Science of Radioligand Therapy

Although it may seem futuristic, radioligand therapy is a safe and proven treatment method for a variety of cancers.

First a scan is performed

Next the drug is administered

The drug then seeks out cancer

Learn about Radioligand Therapies

Our Treatment Pipeline

We are dedicated to expanding access to radiology therapies, making them applicable to more cancers, accessible to more people, and improving the lives of patients and their families. Here are the compounds we are currently developing:

Help improve the lives of patients and their families

We are hiring for clinical, manufacturing and business roles:

Careers at POINT Biopharma

News

POINT Biopharma signs exclusive license agreement with CanProbe for the commercialization of a neuroendocrine tumor treatment

Today it was announced that POINT has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer.

POINT Biopharma Announces New Board Appointments

POINT today announced the appointment of Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour to its Board of Directors.

Announcing licensing and partnership for canSEEK™ pan-cancer targeting technology

POINT today announced that it has entered into a definitive agreement with Bach Biosciences, a company commercializing the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University...